Pfizer's RA drug Xeljanz fails to win EU panel support

04/26/2013 | PharmaTimes (U.K.) · Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against approving Pfizer's rheumatoid arthritis drug Xeljanz, or tofacitinib. The drug improved patients' physical function and RA symptoms but it failed to sufficiently demonstrate "a consistent reduction in disease activity and structural damage to joints," the committee said. Pfizer plans to appeal the recommendation.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC